Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1
From BugSigDB
Reviewed Marked as Reviewed by Folakunmi on 2024-2-15
Subjects
- Location of subjects
- France
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Non-small cell lung carcinoma , Renal cell carcinoma , Disease progression measurement non-small cell cancer of lung,non-small cell cancer of the lung,non-small cell carcinoma of lung,non-small cell carcinoma of the lung,non-small cell lung cancer,non-small cell lung carcinoma,non-small cell lung carcinoma (disease),NSCLC,NSCLC - non-small cell lung cancer,Non-small cell lung carcinoma,hypernephroma,kidney adenocarcinoma,RCC,renal cell adenocarcinoma,renal cell carcinoma,renal cell carcinoma (disease),Renal cell carcinoma,Disease progression measurement,disease progression measurement
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-Responders (progression or death)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Responders (partial response or stable disease)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- non-small cell lung carcinoma or renal carcinoma patients (all samples regardless of ampicillin, colistin, and streptomycin (ATB) anitbiotic treatment) that have been treated with PD-1 blockage with partial response or stable disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 36
- Group 1 sample size Number of subjects in the case (exposed) group
- 42
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Mass spectrometry
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Signature 1
Reviewed Marked as Reviewed by Folakunmi on 2024-2-13
Source: Figure 2b
Description: Comparsion of partial response/ stable disease and progressive disease in fecal samples of all patients with non-small cell lung cell lung carcinoma (NSCLC) or renal cell carcinoma (RCC) reponse at 3 months of PD-1 monoclonal antibodies (mAB) treatment
Abundance in Group 1: increased abundance in Responders (partial response or stable disease)
Signature 2
Reviewed Marked as Reviewed by Folakunmi on 2024-2-13
Source: Figure 2b
Description: Comparsion of partial response/ stable disease and progressive disease in fecal samples of all patients with non-small cell lung cell lung carcinoma (NSCLC) or renal cell carcinoma (RCC) reponse at 3 months of PD-1 monoclonal antibodies (mAB) treatment
Abundance in Group 1: decreased abundance in Responders (partial response or stable disease)
